STOCK TITAN

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Cue Biopharma (Nasdaq: CUE) announced two presentations at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) in Houston, Texas, from November 6-10, 2024. The presentations will focus on their clinical assets CUE-101 and CUE-102, part of the CUE-100 series.

An oral presentation by Dr. Christine Chung will discuss a phase 1 study of CUE-101 as monotherapy and in combination with pembrolizumab for HPV16+ head and neck squamous cell cancer. A poster presentation by Dr. Dae Won Kim will cover a phase 1 trial of CUE-102 for WT1-positive recurrent/metastatic cancers in HLA-A*0201 positive patients.

The oral presentation is scheduled for November 8, 2024, and the poster will be displayed on November 9, 2024. Both presentations will be available as virtual e-posters from November 7, 2024, to January 7, 2025, and on the company's website from November 8, 2024.

Cue Biopharma (Nasdaq: CUE) ha annunciato due presentazioni al 39° Congresso Annuale della Society for Immunotherapy of Cancer (SITC 2024) che si terrà a Houston, Texas, dal 6 al 10 novembre 2024. Le presentazioni si concentreranno sui loro beni clinici CUE-101 e CUE-102, parte della serie CUE-100.

Una presentazione orale della Dr.ssa Christine Chung discuterà di uno studio di fase 1 di CUE-101 come monoterapia e in combinazione con pembrolizumab per il cancro squamoso della testa e del collo HPV16+. Una presentazione poster del Dr. Dae Won Kim coprirà un trial di fase 1 di CUE-102 per tumori recidivanti/metastatici positivi per WT1 in pazienti HLA-A*0201 positivi.

La presentazione orale è programmata per l'8 novembre 2024, mentre il poster sarà esposto il 9 novembre 2024. Entrambe le presentazioni saranno disponibili come e-poster virtuali dal 7 novembre 2024 al 7 gennaio 2025 e sul sito web dell'azienda dall'8 novembre 2024.

Cue Biopharma (Nasdaq: CUE) anunció dos presentaciones en el 39º Congreso Anual de la Sociedad de Inmunoterapia del Cáncer (SITC 2024) que se llevará a cabo en Houston, Texas, del 6 al 10 de noviembre de 2024. Las presentaciones se centrarán en sus activos clínicos CUE-101 y CUE-102, parte de la serie CUE-100.

Una presentación oral de la Dra. Christine Chung discutirá un estudio de fase 1 de CUE-101 como monoterapia y en combinación con pembrolizumab para el cáncer de cabeza y cuello escamoso HPV16+. Una presentación en cartel del Dr. Dae Won Kim abordará un ensayo de fase 1 de CUE-102 para cánceres recurrentes/metastásicos positivos para WT1 en pacientes positivos para HLA-A*0201.

La presentación oral está programada para el 8 de noviembre de 2024, y el cartel se exhibirá el 9 de noviembre de 2024. Ambas presentaciones estarán disponibles como e-posters virtuales del 7 de noviembre de 2024 al 7 de enero de 2025 y en el sitio web de la empresa a partir del 8 de noviembre de 2024.

큐 바이오파마 (Nasdaq: CUE)는 2024년 11월 6일부터 10일까지 텍사스 휴스턴에서 열리는 제39회 암 면역 요법 학회(SITC 2024)에서 두 개의 발표를 발표한다고 발표했습니다. 발표는 CUE-100 시리즈의 일환인 임상 자산 CUE-101 및 CUE-102에 초점을 맞출 것입니다.

크리스틴 청 박사에 의한 구두 발표는 HPV16+ 두경부 편평세포암에 대한 pembrolizumab과 단독 요법 및 병용으로서 CUE-101의 1상 연구에 대해 논의할 것입니다. Dae Won Kim 박사에 의한 포스터 발표는 HLA-A*0201 양성 환자에서 WT1 양성 재발/전이성 암에 대한 CUE-102의 1상 시험을 다룰 것입니다.

구두 발표는 2024년 11월 8일로 예정되어 있으며, 포스터는 2024년 11월 9일에 전시됩니다. 두 발표 모두 2024년 11월 7일부터 2025년 1월 7일까지 가상 e-포스터로 제공되며, 2024년 11월 8일부터 회사 웹사이트에서 확인할 수 있습니다.

Cue Biopharma (Nasdaq: CUE) a annoncé deux présentations lors de la 39e Réunion Annuelle de la Société d'Immunothérapie du Cancer (SITC 2024) qui se tiendra à Houston, Texas, du 6 au 10 novembre 2024. Les présentations se concentreront sur leurs actifs cliniques CUE-101 et CUE-102, faisant partie de la série CUE-100.

Une présentation orale par le Dr. Christine Chung discutera d'une étude de phase 1 de CUE-101 en monothérapie et en combinaison avec le pembrolizumab pour les cancers à cellules squameuses de la tête et du cou HPV16+. Une présentation d'affiche par le Dr. Dae Won Kim abordera un essai de phase 1 de CUE-102 pour les cancers récurrents/métastatiques positifs pour WT1 chez les patients positifs pour HLA-A*0201.

La présentation orale est prévue pour le 8 novembre 2024, et l'affiche sera affichée le 9 novembre 2024. Les deux présentations seront disponibles sous forme de e-posters virtuels du 7 novembre 2024 au 7 janvier 2025, ainsi que sur le site web de l'entreprise à partir du 8 novembre 2024.

Cue Biopharma (Nasdaq: CUE) kündigte zwei Präsentationen auf dem 39. Jahrestreffen der Gesellschaft für Immuntherapie von Krebs (SITC 2024) in Houston, Texas, vom 6. bis 10. November 2024 an. Die Präsentationen werden sich auf ihre klinischen Assets CUE-101 und CUE-102, Teil der CUE-100-Serie, konzentrieren.

Eine mündliche Präsentation von Dr. Christine Chung wird eine Phase-1-Studie von CUE-101 als Monotherapie und in Kombination mit Pembrolizumab für HPV16+-Plattenepithelkarzinome der Kopf-Hals-Region behandeln. Eine Poster-Präsentation von Dr. Dae Won Kim wird eine Phase-1-Studie von CUE-102 für WT1-positive rezidivierende/metastasierende Krebserkrankungen bei HLA-A*0201-positiven Patienten abdecken.

Die mündliche Präsentation ist für den 8. November 2024 angesetzt, und das Poster wird am 9. November 2024 ausgestellt. Beide Präsentationen werden vom 7. November 2024 bis zum 7. Januar 2025 als virtuelle E-Poster verfügbar sein und ab dem 8. November 2024 auf der Website des Unternehmens erhältlich sein.

Positive
  • None.
Negative
  • None.

BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced it will deliver an oral and a poster presentation on the company’s Immuno-STAT™ clinical assets CUE-101 and CUE-102, representative of the CUE-100 series, at the Society for Immunotherapy of Cancer’s 39th Annual Meeting (SITC 2024). The conference will be held in Houston, Texas, on November 6-10, 2024.

Presentation Details
Title: A phase 1 dose-escalation and expansion study of CUE-101 as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer
Abstract Number: 649
Presenter: Dr. Christine Chung, Department Chair, Head and Neck Oncology, Moffitt Cancer Center
Session: Rapid Oral-Clinical 1
Date and Time: Friday, November 8, 2024, 12:30 p.m.–1:30 p.m. CST

Title: A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc T cell engager in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers 
Abstract Number: 636
Presenter: Dr. Dae Won Kim, Moffitt Cancer Center
Session: Poster Session, Exhibit Halls A B George R. Brown Convention Center
Date and Time: Saturday, November 9, 2024, 9:00 a.m.–8:30 p.m. CST

All posters will be available to conference attendees as virtual e-posters on the virtual meeting platform on November 7, 2024, at 9 a.m. CST through January 7, 2025. The oral presentation and poster will also be available on November 8, 2024, in the Investor & Media section of the Company’s website at www.cuebiopharma.com, under Scientific Publications and Presentations.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.

Investor Contact
Marie Campinell 
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com

Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com


FAQ

What presentations will Cue Biopharma (CUE) give at SITC 2024?

Cue Biopharma will give an oral presentation on CUE-101 and a poster presentation on CUE-102 at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) in November 2024.

When and where will SITC 2024 be held?

SITC 2024 will be held in Houston, Texas, from November 6-10, 2024.

What is the focus of Cue Biopharma's (CUE) CUE-101 presentation at SITC 2024?

The CUE-101 presentation focuses on a phase 1 study of the drug as monotherapy and in combination with pembrolizumab for HPV16+ head and neck squamous cell cancer.

Who will present Cue Biopharma's (CUE) CUE-102 poster at SITC 2024?

Dr. Dae Won Kim from Moffitt Cancer Center will present the CUE-102 poster at SITC 2024.

How long will Cue Biopharma's (CUE) SITC 2024 presentations be available online?

The presentations will be available as virtual e-posters from November 7, 2024, to January 7, 2025, and on the company's website from November 8, 2024.

Cue Biopharma, Inc.

NASDAQ:CUE

CUE Rankings

CUE Latest News

CUE Stock Data

99.34M
60.21M
0.55%
26.71%
3.23%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON